Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HCG.NS Stock Summary
Top 10 Correlated ETFs
HCG.NS
In the News
HCG.NS Financial details
Company Rating
Buy
Market Cap
47.48B
Income
352.59M
Revenue
18.56B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6.14K
Optionable
No
Shortable
Yes
Earnings
23 May 2024
P/E
135.8
Forward P/E
48.4
PEG
-34.92
P/S
2.77
P/B
5.87
P/C
-
P/FCF
769.84
Quick Ratio
0.76
Current Ratio
0.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
2.53
EPS next Y
6.98
EPS next Q
1.85
EPS this Y
-49.03%
EPS next Y
176.04%
EPS next 5Y
294.18%
EPS last 5Y
NAN%
Revenue last 5Y
11.97%
Revenue Q/Q
-3.5%
EPS Q/Q
-57.73%
-
-
-
-
SMA20
-9.57%
SMA50
-6.59%
SMA100
-7.36%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
9%
ROC
0.09%
Gross Margin
53%
Oper. Margin
9%
Profit Margin
2%
Payout
-
Shs Outstand
139.29M
Shs Float
31.88M
-
-
-
-
Target Price
-
52W Range
256.1-401.0
52W High
-15.75%
52W Low
+31.97%
RSI
47
Rel Volume
0.72
Avg Volume
195.99K
Volume
141.66K
Perf Week
-1.44%
Perf Month
-7.84%
Perf Quarter
-6.72%
Perf Half Y
-0.07%
-
-
-
-
Beta
0.307
-
-
Volatility
3.86%, 19.9%
Prev Close
0.16%
Price
337.85
Change
2.01%
HCG.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 109.3 | 122.04 | 88.34 | 106.64 | 121.62 | |
Net income per share | -2.82 | -12.05 | -17.02 | 4.14 | 2.11 | |
Operating cash flow per share | 11.21 | 14.7 | 10.6 | 16.97 | 18.09 | |
Free cash flow per share | -10.27 | 2.52 | 7.49 | 11.48 | 8.51 | |
Cash per share | 2.45 | 4.77 | 14.58 | 15.74 | 14.66 | |
Book value per share | 54.22 | 43.06 | 61.34 | 67.1 | 61.88 | |
Tangible book value per share | 45.9 | 31.44 | 52.46 | 51.86 | 48.14 | |
Share holders equity per share | 54.22 | 43.06 | 61.34 | 67.1 | 61.88 | |
Interest debt per share | 80.65 | 166.11 | 95.75 | 76.99 | 72.24 | |
Market cap | 18.23B | 6.56B | 21.65B | 35.01B | 36.5B | |
Enterprise value | 24.61B | 19.71B | 31.13B | 42.18B | 43.77B | |
P/E ratio | -73.53 | -6.15 | -11.19 | 65.15 | 124.37 | |
Price to sales ratio | 1.9 | 0.61 | 2.16 | 2.53 | 2.16 | |
POCF ratio | 18.51 | 5.04 | 17.96 | 15.9 | 14.51 | |
PFCF ratio | -20.2 | 29.39 | 25.44 | 23.51 | 30.84 | |
P/B Ratio | 3.83 | 1.72 | 3.11 | 4.02 | 4.24 | |
PTB ratio | 3.83 | 1.72 | 3.11 | 4.02 | 4.24 | |
EV to sales | 2.56 | 1.82 | 3.1 | 3.05 | 2.59 | |
Enterprise value over EBITDA | 24 | 12.65 | 25.68 | 18.47 | 14.03 | |
EV to operating cash flow | 24.98 | 15.14 | 25.83 | 19.16 | 17.4 | |
EV to free cash flow | -27.26 | 88.28 | 36.58 | 28.33 | 36.98 | |
Earnings yield | -0.01 | -0.16 | -0.09 | 0.02 | 0.01 | |
Free cash flow yield | -0.05 | 0.03 | 0.04 | 0.04 | 0.03 | |
Debt to equity | 1.38 | 3.53 | 1.4 | 1.05 | 1.05 | |
Debt to assets | 0.4 | 0.6 | 0.48 | 0.41 | 0.39 | |
Net debt to EBITDA | 6.22 | 8.44 | 7.82 | 3.14 | 2.33 | |
Current ratio | 0.5 | 0.53 | 0.93 | 1.07 | 1.02 | |
Interest coverage | 0.78 | 0.18 | -0.3 | 0.95 | 1.31 | |
Income quality | -2.95 | -1.09 | -0.53 | 2.51 | 5.61 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.03 | 0.02 | 0.03 | 0.03 | 0.04 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.07 | 0.06 | 0.06 | 0.1 | 0.09 | |
Capex to operating cash flow | -1.92 | -0.83 | -0.29 | -0.32 | -0.53 | |
Capex to revenue | -0.2 | -0.1 | -0.04 | -0.05 | -0.08 | |
Capex to depreciation | -2.22 | -0.73 | -0.22 | -0.45 | -0.82 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 58.66 | 108.05 | 153.28 | 79.08 | 54.2 | |
ROIC | 0.03 | 0.01 | -0.01 | 0.02 | 0.02 | |
Return on tangible assets | -0.02 | -0.05 | -0.1 | 0.03 | 0.01 | |
Graham Net | -105.44 | -183.35 | -85.89 | -71.84 | -71.57 | |
Working capital | -2.74B | -2.72B | -302.86M | 325.92M | 100.3M | |
Tangible asset value | 4.04B | 2.78B | 5.96B | 6.73B | 6.7B | |
Net current asset value | -8.58B | -15.3B | -8.87B | -8.33B | -8.66B | |
Invested capital | 1.38 | 3.53 | 1.4 | 1.05 | 1.05 | |
Average receivables | 1.98B | 2.17B | 2.17B | 2.36B | 2.75B | |
Average payables | 1.62B | 1.68B | 1.5B | 1.7B | 2.21B | |
Average inventory | 253.99M | 250.15M | 221.83M | 255.4M | 341.31M | |
Days sales outstanding | 85.85 | 70.28 | 82.03 | 65.06 | 65.66 | |
Days payables outstanding | 141.95 | 107.09 | 106.26 | 103.78 | 116.24 | |
Days of inventory on hand | 20.92 | 16.22 | 15.41 | 16.04 | 17.91 | |
Receivables turnover | 4.25 | 5.19 | 4.45 | 5.61 | 5.56 | |
Payables turnover | 2.57 | 3.41 | 3.43 | 3.52 | 3.14 | |
Inventory turnover | 17.45 | 22.51 | 23.68 | 22.76 | 20.38 | |
ROE | -0.05 | -0.28 | -0.28 | 0.06 | 0.03 | |
Capex per share | -21.47 | -12.18 | -3.12 | -5.49 | -9.58 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 30.48 | 31.59 | 33.22 | 34.9 | 33.73 | |
Net income per share | 0.54 | 0.6 | 0.55 | 0.97 | 0.41 | |
Operating cash flow per share | 5.86 | 0.47 | 5.93 | 4.57 | 6.35 | |
Free cash flow per share | 5.86 | 0.47 | 5.93 | 0 | 6.35 | |
Cash per share | 11.44 | 14.6 | 14.21 | 10.8 | 0 | |
Book value per share | 64 | 61.65 | 62.84 | 61.6 | 0 | |
Tangible book value per share | 0 | 47.96 | 0 | 46.51 | 0 | |
Share holders equity per share | 64 | 61.65 | 62.84 | 61.6 | 0 | |
Interest debt per share | 1.95 | 66.4 | 1.85 | 72.32 | 2.12 | |
Market cap | 39.98B | 36.63B | 44.06B | 49.8B | 50.79B | |
Enterprise value | 41.57B | 43.9B | 46.03B | 58.42B | 50.79B | |
P/E ratio | 132.56 | 109.3 | 144.75 | 91.74 | 222.74 | |
Price to sales ratio | 9.43 | 8.31 | 9.58 | 10.25 | 10.83 | |
POCF ratio | 49.03 | 562.39 | 53.72 | 78.19 | 57.5 | |
PFCF ratio | 49.03 | 562.39 | 53.72 | 0 | 57.5 | |
P/B Ratio | 4.49 | 4.26 | 5.07 | 5.81 | 0 | |
PTB ratio | 4.49 | 4.26 | 5.07 | 5.81 | 0 | |
EV to sales | 9.81 | 9.96 | 10.01 | 12.02 | 10.83 | |
Enterprise value over EBITDA | 52.52 | 54.22 | 59.71 | 66.37 | 59.97 | |
EV to operating cash flow | 50.98 | 673.93 | 56.12 | 91.72 | 57.5 | |
EV to free cash flow | 50.98 | 673.93 | 56.12 | 0 | 57.5 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0.02 | 0 | 0.02 | 0 | 0.02 | |
Debt to equity | 0 | 1.05 | 0 | 1.14 | 0 | |
Debt to assets | 0 | 0.39 | 0 | 0.41 | 0 | |
Net debt to EBITDA | 2.01 | 8.97 | 2.55 | 9.79 | 0 | |
Current ratio | 0 | 1.02 | 0 | 0.93 | 0 | |
Interest coverage | 1.42 | 1.51 | 1.3 | 1.67 | 1.38 | |
Income quality | 10.81 | 0.78 | 10.78 | 4.69 | 15.49 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.13 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.09 | 0 | 0.09 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | -1 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.13 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -0.76 | 0 | |
Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0 | |
Graham number | 27.94 | 28.86 | 27.89 | 36.75 | 0 | |
ROIC | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0.01 | 0 | |
Graham Net | 11.44 | -71.31 | 14.21 | -81.55 | 0 | |
Working capital | 1.59B | 100.3M | 1.97B | -437.7M | 0 | |
Tangible asset value | 0 | 6.7B | 0 | 6.48B | 0 | |
Net current asset value | 1.59B | -8.66B | 1.97B | -9.65B | 0 | |
Invested capital | 0 | 1.05 | 0 | 1.14 | 0 | |
Average receivables | 1.34B | 1.52B | 1.52B | 1.68B | 1.68B | |
Average payables | 1.15B | 1.24B | 1.24B | 1.4B | 1.4B | |
Average inventory | 187.35M | 191.45M | 191.45M | 208.2M | 208.2M | |
Days sales outstanding | 0 | 62.1 | 0 | 62.12 | 0 | |
Days payables outstanding | 0 | 107.66 | 0 | 110.83 | 0 | |
Days of inventory on hand | 0 | 16.59 | 0 | 16.5 | 0 | |
Receivables turnover | 0 | 1.45 | 0 | 1.45 | 0 | |
Payables turnover | 0 | 0.84 | 0 | 0.81 | 0 | |
Inventory turnover | 0 | 5.42 | 0 | 5.45 | 0 | |
ROE | 0.01 | 0.01 | 0.01 | 0.02 | 0 | |
Capex per share | 0 | 0 | 0 | -4.57 | 0 |
HCG.NS Frequently Asked Questions
What is HealthCare Global Enterprises Limited stock symbol ?
HealthCare Global Enterprises Limited is a IN stock and trading under the symbol HCG.NS
What is HealthCare Global Enterprises Limited stock quote today ?
HealthCare Global Enterprises Limited stock price is $337.85 today.
Is HealthCare Global Enterprises Limited stock public?
Yes, HealthCare Global Enterprises Limited is a publicly traded company.